Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.
The findings, presented during the Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer, indicate the need to develop novel treatments for women with non-mitogen-activated protein kinase (MAPK)-mutated ovarian cancer, according to the researchers.
“We have known for several years that mutations in the MAPK signaling pathway — KRAS, NRAS, BRAF —